ARID1A and cancer: Ideally, a specific large panel should be created including these and other DNA markers identified in other studies, such as NEUROG1, CDKN2A, IGF2, and CRABP1. In the personalized medicine era, NGS-targeted gene panels comprising top-performing markers as cancer-specific mutations (TGFBR2, RNF43, ARID1A, ATM, BRCA2, CTNNB1, and others) may optimize early detection of CRC precursors and increase compliance in these high-risk patients (Figure 3).